Summary This study aimed to assess the safety and efficacy of using high dose melphalan and etoposide followed by autologous, non-cryopreserved marrow rescue in advanced Hodgkin's disease (HD).
Autologous bone marrow transplantation (ABMT) is used increasingly in the treatment of lymphoid malignancies. Our Group has used ABMT as part of intensification therapy in acute lymphoblastic leukemia (ALL) in first CR since 1984 (Proctor et al., 1985; Proctor et al., 1988) and in poor prognosis non-Hodgkin's lymphoma (NHL) in first CR since 1985 (Carey et al., 1991) . The conditioning regimen used in ALL and NHL has been melphalan alone (3mgkg-' body weight) or melphalan (3 mg kg-' body weight) plus total body irradiation (TBI) (1050 cGy in three fractions of 350 cGy). Marrow rescue has utilised non-cryopreserved, nonpurged marrow. We have found this to be a safe procedure and details of the rate of haematopoietic reconstitution, lack of toxicity and efficacy have been published elsewhere (Carey et al., 1991) . There has been no procedural mortality in the groups of patients mentioned.
During 1986, we formulated a numerical prognostic index with the intention of identifying at diagnosis those HD patients destined to die of their disease. Such patients were to be given alternative, more aggressive, first line treatment. The index allowed us to separate poor prognosis patients from those who would be cured with four drug CLVPP/MOPP type regimens, thus avoiding over-treating this latter group . This approach has now been modified and refined by the addition of a factor for bulk disease (Proctor et al., 1992) and the Scotland and Newcastle Lymphoma Group (SNLG) is undertaking a trial of ABMT versus intensive conventional therapy in poor risk patients (Proctor et al., 1992) . The high dose intensification for this trial was chosen, in part, as a result of data emerging from the patients described in the present paper. The choice of preconditioning for HD was based on our experience with melphalan in high grade non-Hodgkin's lymphoma autotransplants and the fact that it had been shown to have value in other series of ABMT in HD (Russell et al., 1989; Zulian et al., 1989) . It was considered that VP16, known to be an active agent in HD, used at high dose would be of benefit Wolff et al., 1983; Blume et al., 1987; Jagannath et al., 1986; Stewart et al., 1991) . All agents for this procedure needed a short half-life if our policy of using non-cryopreserved marrow, which is associated with rapid engraftment and lack of procedural mortality (Carey et al., 1991) (range 19-46) . Two patients had primary resistant disease, two were in fourth relapse, six were in second or subsequent complete remission and seven had ABMT following primary therapy, six in first CR and one in maximal first response (GPR) (>75% reduction). The latter seven patients were all judged poor risk by the SNLG prognostic index (Table I) Proctor et al., 1992 Bowel decontamination was achieved using non-absorbable antibiotics (colistin and vancomycin) and prophylactic antiviral (acyclovir) and anti-fungal (nystatin and amphotericin) therapy was given. All blood products were irradiated and CMV -ve.
Multiple-donor platelet transfusions were given if platelets were <20 x 1091-and red blood cell transfusions if Hb <100 g-'. Fever > 380C was treated empirically with broad spectrum antibiotics. Patient 5 received 5 itg kg-' of G-CSF (Chugai) as part of a clinical trial.
Results

Haematologic reconstitution
Complete marrow re-engraftment occurred in 16 of the 17 patients. One patient died of progressive HD with partial engraftment. The rate of reconstitution was most rapid in those transplanted in first CR (Table III) . The median number of days <0.5 x 109 1' neutrophils and the days of platelet support in patients having transplant in first CR were less than those whose transplants were performed in subsequent CR. Those (Lennard et al., 1990) went into remission and remains in CR at 53 months post transplant. Two patient with resistant disease were transplanted and both demonstrated a temporary partial response (Table II) . Two patients transplanted after fourth relapse showed good response to ABMT; their transplants had been perceived as salvage therapy; but both went into CR. One patient remains in CR 15 months post transplant and the other relapsed at 18 months.
Discussion
Ann Arbor staging has been enormously valuable over the last two decades whilst investigators have attempted to optimise treatment for Hodgkin's disease. It has been known for some time that 40-50% of patients with Stage IIIB and Stage IV Hodgkin's disease could achieve a sustained CR with four drug chemotherapy schedules such as MOPP (mustine, vincristine, prednisolone and procarbazine), CLVPP (chlorambucil, vinblastine, prednisolone and procarbazine) or ABVD (doxorubicin, bleomycin, vincristine and DTIC). However 50-60% of patients with advanced stage disease do not do well with these regimens and a number of new alternating (Bonadonna et al., 1986) or hybrid (Klimo et al., 1988) combinations have been used. This approach exposes the patients to an increased number of drugs and their potential attendant risk of additional early and late side effects. Such studies have been conducted on patients with Stage IIIB and IV disease and patients in these staging groups who were destined to respond to four drug schedules have been included. The inclusion of these 'good responders' means that the increased efficacy which has been suggested for hybrid regimens has been difficult to quantitate.
It is possible to use prognostic factors objectively and add their weight to classical Ann Arbor staging to produce a numerical formula to predict those patients of all stages who are unlikely to be cured by conventional four drug regimens. Details of the SNLG numerical prognostic index were published recently . This index was derived and validated on over 500 cases within the SNLG files. It was created using data from patients treated with four drug combinations and is valid for such a Hodgkin's disease patient population base. In a more recent publication (Proctor et al., 1992) our group has indicated that the index can be enhanced by an additional factor for bulk. This modified index is in use to identify patients who require aggressive therapy from the time of diagnosis of their HD (Proctor et al., 1992) .
Having identified poor risk patients in our population an aggressive chemotherapeutic regime was formulated for them which included intensification with autotransplant in first remission. A continuous hybrid chemotherapy schedule (PVACE-BOP) was evolved (Proctor et al., 1992) and the details of this are shown in Figure I . The majority of patients in the present study, who underwent ABMT in first or subsequent remission, received this therapy as either first or second line treatment prior to high dose chemotherapy with autotransplant (Table II) .
Classical BEAM (BCNU, etoposide, melphalan, cytosine arabinoside) (Gribben et al., 1989) or CBV (cyclophosphamide, carmustine and etoposide) (Armitage et al., 1991; Reece et al., 1991; Jagannath et al., 1989 ) ablative chemotherapy as preconditioning was considered inappropriate as intensification for patients in 1st CR because of the known toxicity and associated mortality. Our aim in these patients is to attack the minimal residual disease which may not required the same degree of chemotherapeutic intensity developed for treating patients in later stages of disease.
Non-cryopreserved marrow rescue was used as this is associated with a lack of major procedural toxicity and rapid engraftment (Carey et al., 1991; Russell et al., 1989; Koppler et al., 1992) . The preconditioning consisted of melphalan and etoposide (VP16), whose short half-life made cryopreservation unnecessary. Patients have not experienced any major toxicity to date.
To conclude, we believe that we have evolved a logical sequence of treating those patients we consider are at high risk of dying from progressive HD in the first 4 years from diagnosis. We therefore:
(1) Identify the poor risk population using the SNLG prognostic index. (2) Treat the poor risk group with aggressive chemotherapy from the outset, utilising an eight drug regime which is given continuously for 12 weeks (PVACE-BOP) rather than CLVPP. (3) Utilise high dose intensification with melphalan/VP16 and ABMT, using pilot information on toxicity and efficacy reported above. In this way the 40-50% of patients with Stage III or IV Hodgkin's disease who are destined to be cured of their disease with a four drug regimen alone, are not overtreated, and, therefore, are not at increased risk of secondary complications of therapy.
The question of whether patients at risk of early relapse will benefit from high dose chemotherapy with ABMT following intensive primary therapy still remains. Having provided this pilot information on the toxicity and efficacy of ABMT for the SNLG, there is now a prospective randomised trial in progress to try and answer this question (Proctor et al., 1992) .
